Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Personalized Medical Oncology

Prof. Dr. Dr. Sonja Loges

Mechanism of Axl inhibition by Bemcentinib
© dkfz.de

Recent improvements in specific targeting of genomic and immunosuppressive cancer drivers have led to major advances in the treatment of malignant tumors. Personalized oncology treats patients according to these specific disease mechanisms of their individual tumors. This strategy has proven successful in some cancer entities including melanoma, breast cancer and non-small cell lung cancer (NSCLC) yielding unprecedented survival even in advanced disease. However, the majority of patients still do not reach long-term survival because they eventually develop resistance mainly due to complex and heterogenous escape mechanisms evolving under treatment pressure.

Our group identifies novel mechanisms driving cancer progression and therapy resistance with a focus on the tumor microenvironment. From these functional insights we derive novel targets and identify treatments for individualized cancer therapies. After preclinical validation we translate them into clinical studies. For example, we found that the interaction of AML cells with the bone marrow stroma elicits upregulation of its ligand Gas6 driving therapy resistance of AML cells and immunosuppression via engaging its receptor Axl in AML or immune cells, respectively (Ben-Batalla et al, Blood 2013). This pathway can be inhibited by the small molecule Axl inhibitor Bemcentinib which we translated into a clinical trial in relapsed AML patients (BGBC003, NCT02488408). In a reverse translation program attached to the trial we are dissecting patterns of response and resistance with innovative single cell sequencing technologies in order to inform further development of Axl-targeting.

In addition, we investigate patterns of response and resistance to targeted and immune therapies in cancer with a focus on precision oncology and NSCLC by utilizing innovative solid & liquid biopsy technologies. Here, we apply microfluidics techniques as well as single cell sequencing and -imaging technologies to enrich & analyze tumor cell as well as other cellular and subcellular components present in tumors and/or body fluids of cancer patients. Thereby, we identify unknown potential resistance mechanisms which we investigate in-depth at the functional level in cellular and animal cancer models concerning their capability to drive cancer progression and therapy resistance. Potentially druggable candidates are subsequently translated to clinical trials.

Overall, we aim to discover novel tumor-promoting mechanisms at the interface between tumor and host, derive novel therapies and dissect mechanisms of response and resistance in cancer patients.

Contact

Prof. Dr. Dr. Sonja Loges
Personalized Medical Oncology (A420)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg

Phone Office: +49 621 383-1757
Phone Lab: +49 6221 42 3435

E-Mail:
simone.kungl@dkfz-heidelberg.de
Victoria.Gensch@dkfz-heidelberg.de

Selected Publications

  • Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel HD, Wiesweg M, Schildhaus HU, Stratmann JA, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld FC, Wermke M, Merkelbach-Bruse S, Hillmer AM, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol. 2022 Mar 6:S0923-7534(22)00361-1.
  • Westphalen B.C., Bokemeyer C, Büttner R., Fröhling S., Gaidzik V.I., Glimm H., Hacker U.T., Heinemann V., Illert A.L., Keilholz U., Kindler T., Kirschner M., Schilling B., Siveke J.T., Schroeder T., Tischler V., Wagner S., Weichert W., Zips D., Loges S. (2020). Working Group Molecular Diagnostics and Therapy, Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. Eur J Cancer: Aug;135:1-7
  • Bauer R.*, Udonta F.*, Wroblewski M., Ben-Batalla I., Santos I.M., Taverna F., Kuhlencord M., Gensch V., Päsler S., Vinckier S., Brandner J.M., Pantel K., Bokemeyer C., Vogl T., Roth J., Carmeliet P., Loges S. (2018). Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy., Cancer Research: 78 (12): 3220-3232 (* equal contribution)
  • Wroblewski M., Bauer R., Cubas Córdova M., Udonta F., Ben-Batalla I., Legler K., Hauser C., Egberts J., Janning M., Velthaus J., Schulze C., Pantel K., Bokemeyer C., Loges S. (2017). Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B. Nat Commun. Aug 16;8(1):269.
to top
powered by webEdition CMS